Evidence map›Paper›PMID 35399316›Full record

ArticleCancer diagnosis & prognosis

Survival Benefit of Neoadjuvant Chemotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction.

Satoshi Suzuki, Shingo Kanaji, Naoki Urakawa, Gosuke Takiguchi, Hiroshi Hasegawa, Yoshiko Matsuda, Kimihiro Yamashita, Takeru Matsuda, Taro Oshikiri, Tetsu Nakamura and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Satoshi SuzukiDivision of Gastrointestinal Surgery, Department of Surgery,Graduate School of Medicine, Kobe University, Kobe, Japan.
Shingo KanajiDivision of Gastrointestinal Surgery, Department of Surgery,Graduate School of Medicine, Kobe University, Kobe, Japan.
Naoki UrakawaDivision of Gastrointestinal Surgery, Department of Surgery,Graduate School of Medicine, Kobe University, Kobe, Japan.
Gosuke TakiguchiDivision of Gastrointestinal Surgery, Department of Surgery,Graduate School of Medicine, Kobe University, Kobe, Japan.
Hiroshi HasegawaDivision of Gastrointestinal Surgery, Department of Surgery,Graduate School of Medicine, Kobe University, Kobe, Japan.
Yoshiko MatsudaDivision of Gastrointestinal Surgery, Department of Surgery,Graduate School of Medicine, Kobe University, Kobe, Japan.
Kimihiro YamashitaDivision of Gastrointestinal Surgery, Department of Surgery,Graduate School of Medicine, Kobe University, Kobe, Japan.
Takeru MatsudaDivision of Gastrointestinal Surgery, Department of Surgery,Graduate School of Medicine, Kobe University, Kobe, Japan.
Taro OshikiriDivision of Gastrointestinal Surgery, Department of Surgery,Graduate School of Medicine, Kobe University, Kobe, Japan.
Tetsu NakamuraDivision of Gastrointestinal Surgery, Department of Surgery,Graduate School of Medicine, Kobe University, Kobe, Japan.
Yoshihiro KakejiDivision of Gastrointestinal Surgery, Department of Surgery,Graduate School of Medicine, Kobe University, Kobe, Japan.
Kobe University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: Adenocarcinoma of the esophagogastric junction (AEG) is refractory even when curative resection is followed by adjuvant chemotherapy. This study evaluated the efficacy of neoadjuvant chemotherapy (NAC) using an oral fluoropyrimidine-platinum regimen for AEG. Patients and Methods: Out of 35 patients with locally advanced AEG who underwent curative resection, 21 who underwent surgery first and 14 who received NAC were retrospectively compared in terms of survival. Results: The NAC regimens comprised of S-1 or capecitabine plus oxaliplatin or cisplatin; trastuzumab was added to six borderline resectable cases. The downstaging rate was 50% and the pathological response rate including complete response (29%) was 50%. The three-year relapse-free survival in the NAC group was significantly superior than the surgery-first group (78% vs. 22%, p=0.011). The NAC group had a significantly longer median survival time than the surgery-first group (NR vs. 29 months, p=0.032). Conclusion: NAC using an oral fluoropyrimidine-platinum regimen may provide survival benefit in AEG.

Indexed as

Adenocarcinoma of esophagogastric junctionneoadjuvant chemotherapyprognosis

Identifiers

PMID35399316
PMCPMC8962799
OpenAlexW3209320905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.